Keeping a Healthy Heart: What You Should Know

Heart Disease's Persistent Grip

Heart disease continues to dominate mortality statistics in the United States. The American Heart Association's 2026 Heart Disease and Stroke Statistics Update, released in January, confirms that cardiovascular diseases, including heart disease and stroke, accounted for over a quarter of all U.S. deaths in 2023—the most recent full year of data—with 915,973 fatalities recorded. This marks a welcome decline from the pandemic peaks of 942,000 in 2022, when disruptions to routine care and direct viral effects on the heart drove numbers upward.

Despite the downturn, the underlying burden remains immense. Someone died of cardiovascular disease every 34 seconds in 2023. Coronary heart disease alone caused 349,470 deaths that year. Stroke has climbed to the fourth leading cause of death, displacing COVID-19, which fell to tenth.

Risk factors tell a more troubling story. Hypertension prevalence among adults showed no meaningful improvement from 2009 to 2023, yet hypertension-linked cardiovascular deaths nearly doubled between 2000 and 2019. Type 2 diabetes prevalence increased from 11.9% to 14.1% over roughly the same period, with associated mortality rising sharply. Obesity continues its epidemic trajectory across demographics, fueling a newly emphasized cardiovascular-kidney-metabolic syndrome that ties metabolic dysfunction to heightened heart and kidney risks.

These trends intersect with persistent disparities. Gains in mortality reduction have slowed or reversed for certain conditions, hitting younger adults and lower-income groups hardest. Treatment gaps persist—only about half of those who could benefit from guideline-recommended medications for cholesterol or blood pressure actually receive them. The economic toll is substantial, with heart disease and related risks generating high annual medical costs, often from preventable acute events like heart attacks and strokes.

Non-obvious tensions emerge in the data. While overall deaths are falling as life expectancy rebounds post-pandemic, the stall in controlling modifiable risks suggests complacency or systemic barriers in prevention. Advances in treatments offer hope, but without broader lifestyle and access improvements, the disease's long-term trajectory could worsen, particularly as interconnected syndromes like cardiovascular-kidney-metabolic gain recognition.